Aurinia Pharmaceuticals Q1 2024 GAAP EPS $(0.07) Beats $(0.14) Estimate, Sales $50.300M Beat $47.453M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals reported Q1 2024 earnings with a GAAP EPS of $(0.07), surpassing the $(0.14) estimate. Sales reached $50.3M, exceeding the $47.453M forecast, marking a 46.18% increase from the previous year.

May 02, 2024 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals exceeded Q1 2024 EPS and sales estimates, showing significant year-over-year growth.
Beating both EPS and sales estimates significantly, especially with a notable year-over-year sales increase, suggests strong operational performance and market confidence, likely leading to a positive short-term stock price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100